BACKGROUND AND AIMS: Fibrosis regression (FR) after sustained virological response (SVR) should produce a better outcome in hepatitis C (HCV)-/HIV-coinfected patients with liver cirrhosis, but there are no specific data in this issue. METHODS: We compared the incidence rate (IR) and the time to develop a liver complication and death in 133 cirrhotic patients according to SVR or/and FR. RESULTS: Of 42 patients with SVR, 23 (55%) had FR, in comparison with only 14 of the 91 (15%) without SVR. During a follow-up of 6.8 years (916.8 person-years), the IR of death, liver-related death, and liver-related complications were 2.45, 0.61, and 1.22 per 100 persons/year among SVR/FR, and 7.6, 5.9, and 6.81 among non-SVR without FR (p < 0.01), respectively. SVR patients without FR had also a lower rate of liver-related complications (1.78 vs 3.25; p = 0.02), but a worse IR of death (5.36) and liver-related death (2.68) than non-SVR patients with FR (1.3, and 0.65; p < 0.01). Moreover, FR was associated with less hospital admissions and decreasing alpha-fetoprotein levels. In Cox analysis, only FR was associated with a lower risk of death (adjusted hazard ratio, HR 0.36; 95% CI 0.15-0.86), and liver-related death (HR 0.15; 95% CI 0.03-0.65), whereas both FR (HR 0.09; 95% CI 0.03-0.3, p < 0.01) and SVR (HR 0.24; 95% CI 0.07-0.87) decreased the risk of liver-related complications. CONCLUSION: Fibrosis regression after SVR is associated with the highest reduction in death of any cause, liver-related mortality, and liver-related complications in HIV-/HCV-coinfected patients with cirrhosis.
BACKGROUND AND AIMS: Fibrosis regression (FR) after sustained virological response (SVR) should produce a better outcome in hepatitis C (HCV)-/HIV-coinfectedpatients with liver cirrhosis, but there are no specific data in this issue. METHODS: We compared the incidence rate (IR) and the time to develop a liver complication and death in 133 cirrhotic patients according to SVR or/and FR. RESULTS: Of 42 patients with SVR, 23 (55%) had FR, in comparison with only 14 of the 91 (15%) without SVR. During a follow-up of 6.8 years (916.8 person-years), the IR of death, liver-related death, and liver-related complications were 2.45, 0.61, and 1.22 per 100 persons/year among SVR/FR, and 7.6, 5.9, and 6.81 among non-SVR without FR (p < 0.01), respectively. SVR patients without FR had also a lower rate of liver-related complications (1.78 vs 3.25; p = 0.02), but a worse IR of death (5.36) and liver-related death (2.68) than non-SVR patients with FR (1.3, and 0.65; p < 0.01). Moreover, FR was associated with less hospital admissions and decreasing alpha-fetoprotein levels. In Cox analysis, only FR was associated with a lower risk of death (adjusted hazard ratio, HR 0.36; 95% CI 0.15-0.86), and liver-related death (HR 0.15; 95% CI 0.03-0.65), whereas both FR (HR 0.09; 95% CI 0.03-0.3, p < 0.01) and SVR (HR 0.24; 95% CI 0.07-0.87) decreased the risk of liver-related complications. CONCLUSION:Fibrosis regression after SVR is associated with the highest reduction in death of any cause, liver-related mortality, and liver-related complications in HIV-/HCV-coinfectedpatients with cirrhosis.
Authors: Juan Berenguer; Elena Rodríguez; Pilar Miralles; Miguel A Von Wichmann; José López-Aldeguer; Josep Mallolas; María J Galindo; Eva Van Den Eynde; María J Téllez; Carmen Quereda; Antoni Jou; José Sanz; Carlos Barros; Ignacio Santos; Federico Pulido; Josep M Guardiola; Enrique Ortega; Rafael Rubio; Juan J Jusdado; María L Montes; Gabriel Gaspar; Herminia Esteban; José M Bellón; Juan González-García Journal: Clin Infect Dis Date: 2012-05-18 Impact factor: 9.079
Authors: J Foucher; E Chanteloup; J Vergniol; L Castéra; B Le Bail; X Adhoute; J Bertet; P Couzigou; V de Lédinghen Journal: Gut Date: 2005-07-14 Impact factor: 23.059
Authors: Juan Berenguer; Julio Alvarez-Pellicer; Ana Carrero; Miguel A Von Wichmann; José López-Aldeguer; Josep Mallolas; María J Galindo; Eva Van Den Eynde; María J Téllez; Carmen Quereda; Cristina Tural; José Sanz; Carlos Barros; Ignacio Santos; Federico Pulido; Josep M Guardiola; Enrique Ortega; Rafael Rubio; Juan J Jusdado; María L Montes; Gabriel Gaspar; Elena Barquilla; José M Bellón; Juan González-García Journal: J Hepatol Date: 2013-02-07 Impact factor: 25.083
Authors: Juan Macías; Angela Camacho; Miguel A Von Wichmann; Luis F López-Cortés; Enrique Ortega; Cristina Tural; Maria J Ríos; Dolores Merino; Francisco Téllez; Manuel Márquez; María Mancebo; Juan A Pineda Journal: AIDS Date: 2013-10-23 Impact factor: 4.177
Authors: Stuart Roberts; Adam Gordon; Catriona McLean; John Pedersen; Scott Bowden; Kenneth Thomson; Peter Angus Journal: Clin Gastroenterol Hepatol Date: 2007-06-04 Impact factor: 11.382
Authors: Pablo Barreiro; Pablo Labarga; Luz Martín-Carbonero; Aranzazu Amor; Andrés Ruiz-Sancho; Carol Castellares; Juan González-Lahoz; Vincent Soriano Journal: Antivir Ther Date: 2006
Authors: Julia B Balmaceda; Julia Aepfelbacher; Olivia Belliveau; Chloe S Chaudhury; Cheryl Chairez; Mary McLaughlin; Rachel Silk; Chloe Gross; Sarah Kattakuzhy; Elana Rosenthal; Shyam Kottilil; David E Kleiner; Colleen Hadigan Journal: Antivir Ther Date: 2019
Authors: Sweta Chekuri; Jillian Nickerson; Kian Bichoupan; Roberta Sefcik; Kamini Doobay; Sanders Chang; David DelBello; Alyson Harty; Douglas T Dieterich; Ponni V Perumalswami; Andrea D Branch Journal: PLoS One Date: 2016-07-21 Impact factor: 3.240
Authors: Sarah Shili-Masmoudi; Philippe Sogni; Victor de Ledinghen; Laure Esterle; Marc-Antoine Valantin; Isabelle Poizot-Martin; Anne Simon; Eric Rosenthal; Karine Lacombe; Gilles Pialoux; Olivier Bouchaud; Anne Gervais-Hasenknoff; Cécile Goujard; Lionel Piroth; David Zucman; Stéphanie Dominguez; François Raffi; Laurent Alric; Firouzé Bani-Sadr; Caroline Lascoux-Combe; Daniel Garipuy; Patrick Miailhes; Daniel Vittecoq; Claudine Duvivier; Hugues Aumaître; Didier Neau; Philippe Morlat; François Dabis; Dominique Salmon; Linda Wittkop Journal: PLoS One Date: 2019-01-25 Impact factor: 3.240